Thursday September 11, 2014

Growth: +22% in kit sales

Marseille, September 11, 2014 - QIAGEN Marseille (Alternext - FR0010626028 - ALIPS), a subsidiary of the QIAGEN Group (previously IPSOGEN), a cancer profiling company that develops, manufactures and markets molecular diagnostic tests for leukemia and cancer, today announced full-year 2014 results that were approved by the Board of Directors on September10, 2014.

The financial information for the period from January 1, 2014, to June 30, 2014, is based on the principles of recognition and measurement set out in the IFRS accounting standards.
The IFRS financial reporting, has been voluntarily established in order to be comparable with previously reported financial information.


See press release
See financial repport

distributed by